5-氨基-4-氰基-3-甲基-1-苯基-1H-吡唑 | 5346-56-5

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氨基-4-氰基-3-甲基-1-苯基-1H-吡唑
• 中文别名: 5-氨基-4-氰基-3-甲基-1-苯甲基吡唑
• 英文名称: 5-amino-3-methyl-1-phenyl-1H-pyrazole-4-carbonitrile
• 英文别名: 1-phenyl-3-methyl-4-cyano-5-aminopyrazole；5-amino-3-methyl-1-phenylpyrazole-4-carbonitrile
• CAS: 5346-56-5
• 化学式: C₁₁H₁₀N₄
• mdl: MFCD00128285
• 分子量: 198.227
• InChiKey: VWOYPUVIGCTVSC-UHFFFAOYSA-N

物化性质

• 熔点：
  129 °C
• 沸点：
  408.2±45.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  67.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2933199090
• 储存条件：
  请将药品存放在避光、阴凉干燥的地方，并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Amino-4-cyano-3-methyl-1-phenyl-1H-pyrazole
Synonyms: 5-Amino-3-methyl-1-phenyl-1H-pyrazole-4-carbonitrile

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Amino-4-cyano-3-methyl-1-phenyl-1H-pyrazole
CAS number: 5346-56-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H10N4
Molecular weight: 198.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氨基-4-氰基-3-甲基-1-苯基-1H-吡唑 在 4-二甲氨基吡啶 、 硫酸 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 3,6-dimethyl-1-phenyl-1,5-dihydro-4H-pyrazolo-[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  吡唑并嘧啶酮作为西地那非衍生物和核黄素的合成

  摘要：

  摘要 从各种吡唑酰胺（2a-d）合成了一系列新型吡唑并嘧啶酮衍生物（3（a-d）、4（a-d）和6（a-d）） 5-amino-3-methyl-1-phenyl-1H-pyrazole-4-carboxylate (1) 和各种氨基锂。此外，我们还描述了从简单的2-硝基苯甲酸以高产率合成具有喹唑啉部分的硬化素药物分子。图形概要

  DOI：

  10.1080/00397911.2018.1459720
• 作为产物：
  描述：

  5-氯-3-甲基-1-苯基吡唑 在 吡啶 、 sodium azide 、 盐酸羟胺 、 四丁基溴化铵 、 铁粉 、 氯化铵 、 三氯氧磷 作用下， 以 乙醇 、 二甲基亚砜 、 乙酸乙酯 为溶剂， 反应 37.5h， 生成 5-氨基-4-氰基-3-甲基-1-苯基-1H-吡唑
  参考文献：
  名称：

  新型融合的吡唑并[4,3-d]吡啶和吡唑并[3,4-b] [1,8]萘啶异构体的设计，合成及药理作用：一类新型的有效和选择性乙酰胆碱酯酶抑制剂。

  摘要：

  一个新的他克林（THA）类似物家族（7-9，12），包含氮杂杂环吡唑并[4,3-d]吡啶或吡唑并[3,4-b] [1,8]萘啶系统，是喹啉的等排体THA环已合成。使用Ellman方法在大鼠脑胆碱酯酶中测试了这些化合物，所有这些化合物均能有效抑制该酶。化合物9和12b对乙酰胆碱酯酶（AChE）最有效，显示IC（50）为6.0和6.4 microM，对大鼠脑丁酰胆碱酯酶的活性较低，分别显示选择性指数5.3和20.9。还使用培养的大鼠皮层细胞在体外测试了化合物7-9和12的急性神经毒性。化合物7和8没有明显毒性；9在500 microM时有毒，但在100 microM时无毒。萘啶衍生物12a和12b表现出明显的浓度依赖性神经毒性，能够杀死500 microM的大多数细胞。使用来自加州鱼雷的AChE的X射线晶体结构的分子动力学模拟来解释这些新的THA等位基因的可能结合方式。

  DOI：

  10.1021/jm020391n

文献信息

• [EN] BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE URÉE, THIOURÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078408A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  式I化合物或其立体异构体、互变异构体或药学上可接受的盐、溶剂合物或前药，其中环A、环C和X如本文所定义，是TrkA激酶的抑制剂，并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
• Synthesis of New Pyrazolopyrimidinedithiones and Pyrazolopyrimidinephosphines from Aminocyanopyrazoles
  作者：Fatma Allouche、Fahker Chabchoub、Mansour Salem、Gilbert Kirsch

  DOI：10.1080/00397911.2010.486516

  日期：2011.4.19

  Abstract A general, high-yielding synthetic protocol for the expedited synthesis of functionalized pyrazolopyrimidine dithione 2 and pyrazolodiazaphosphininethione 3 from amino-cyano pyrazole 1 precursors is presented.

  摘要 提出了一种从氨基-氰基吡唑 1 前体快速合成官能化吡唑并嘧啶二硫酮 2 和吡唑二氮杂膦硫酮 3 的通用、高产合成方案。
• Synthesis of aminocyanopyrazoles via a multi-component reaction and anti-carbonic anhydrase inhibitory activity of their sulfamide derivatives against cytosolic and transmembrane isoforms
  作者：Fatma Allouche、Fakher Chabchoub、Fabrizio Carta、Claudiu T. Supuran

  DOI：10.3109/14756366.2012.720573

  日期：2013.4.1

  were converted to the corresponding sulfamides by reaction with sulfamoyl chloride. The aminopyrazoles incorporating phenyl and tosyl moieties were tested as inhibitors of four carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the human (h) hCA I, II, IX and XII. Many of them showed low micromolar or submicromolar inhibition of these enzymes. The corresponding sulfamides were low nanomolar CA inhibitors.

  描述了在酸性催化剂下丙二腈与原酸酯和肼衍生物之间多组分反应（MCR）的便捷方案。制备，分离和表征了一系列氨基氰基吡唑4。这些吡唑与亚硝酸钠，然后与仲胺试剂和甲酸反应，生成吡唑并三嗪6和吡唑并吡喃二酮7。一些氨基吡唑通过与氨磺酰氯反应转化为相应的磺酰胺。测试了结合有苯基和甲苯磺酰基部分的氨基吡唑类化合物作为四种碳酸酐酶（CA，EC 4.2.1.1）同种型（人）hCA I，II，IX和XII的抑制剂。它们中的许多显示出对这些酶的低微摩尔或亚微摩尔抑制。相应的磺酰胺为低纳摩尔CA抑制剂。
• Synthesis and properties of sildenafil isostere
  作者：Ziqi Su、Qi Zhang、Qieqiang Zhao、Wenyi Liu、Tao Zhao、Huiping Wang、Jiarong Li、Juan Xu

  DOI：10.1002/ardp.202100145

  日期：2021.10

  series of novel pyrazolo[3,4-d]pyrimidin-4-one derivatives were synthesized and evaluated for their anti-phosphodiesterase-5 (PDE-5) activity. A total of 28 compounds, containing alkyl and aryl groups at the 1-N and 3-C positions on the pyrazole ring, and also bearing different alkyl substituents on the piperazine ring were synthesized. Four compounds (4d, 5d, 6d, and 5o) were found to have better

  合成了一系列新型吡唑并[3,4- d ]嘧啶-4-酮衍生物，并评估了它们的抗磷酸二酯酶5 (PDE-5) 活性。共合成了 28 种化合物，它们在吡唑环的 1-N 和 3-C 位含有烷基和芳基，在哌嗪环上也带有不同的烷基取代基。发现四种化合物（4d、5d、6d和5o）对 PDE-5 具有更好的抑制活性（IC 50  < 10 nM）。所有四种最活跃的化合物都在 N1 位包含一个苯环。含有 3,5-二甲基哌嗪基的化合物比其他化合物表现出更好的活性。这些结果表明化合物5o可用作开发新的 PDE-5 抑制剂的先导结构。
• [EN] N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-(ARYLALKYLE)-N'-PYRAZOLYLE-URÉE, DE THIOURÉE, DE GUANIDINE ET DE CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078331A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  公式I的化合物或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C、X、Ra、Rb、Rc、Rd和n如本文所述定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。

表征谱图